| Short facts | |
| API | Adrenaline |
| Technology | amorphOX™, nasal powder technology |
| Indication | Emergency treatment of allergic reactions |
| Development phase | Expects to perform first explorative human clinical pharmacokinetic study in the second half of 2022. |
| Expected filing with FDA | - |
| In-house or partnership | In-house |
Adrenaline is commonly used for the emergency treatment of allergic reactions, including anaphylaxis, which is a global and growing health problem. The market is currently dominated by the use of auto-injectors for intramuscular or subcutaneous administration of injection solutions of adrenaline, although new delivery alternatives are under development.
Adrenaline is a very unstable active ingredient sensitive to chemical degradation, which is the reason why today’s commercial adrenaline products have limited shelf-life with restrictive storage conditions.
Our aim
With OX640, Orexo wants to offer patients a more comfortable and needle-free alternative to auto-injectors currently on the market. Since adrenaline is a very unstable active ingredient, the product also aims to offer increased flexibility in relation to how adrenaline products can be handled and stored. In that way, we can provide significant benefits to patients and healthcare systems, ensuring the correct adrenaline dose is available when needed.
To attain these goals, OX640 is based on Orexo’s proprietary drug delivery platform amorphOX™ - a platform which shows promising chemical and physical stability data.